Metabolic Responses to Dietary Protein Restriction Require an Increase in FGF21 that Is Delayed by the Absence of GCN2  by Laeger, Thomas et al.
ArticleMetabolic Responses to Dietary Protein Restriction
Require an Increase in FGF21 that Is Delayed by the
Absence of GCN2Graphical AbstractHighlightsd Protein restriction increases FGF21 acutely and persistently
d FGF21 is required for the metabolic and behavioral response
to protein restriction
d GCN2 is only transiently required for the response to protein
restriction
d Pathways upstream of ATF4 compensate for the absence of
GCN2 and induce FGF21Laeger et al., 2016, Cell Reports 16, 707–716
July 19, 2016 ª 2016 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2016.06.044Authors
Thomas Laeger, Diana C. Albarado,
Susan J. Burke, ..., J. Jason Collier,
HeikeM€unzberg, Christopher D. Morrison
Correspondence
morriscd@pbrc.edu
In Brief
Laeger et al. demonstrate that FGF21 is
required for adaptive metabolic
responses to protein restriction. The
amino acid sensor GCN2 initially
contributes to the induction of FGF21, but
additional mechanisms compensate for
its absence over longer periods.
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FGF21 contributes to the metabolic response to
dietary protein restriction, and prior data implicate
GCN2 as the amino acid sensor linking protein re-
striction to FGF21 induction. Here, we demonstrate
the persistent and essential role of FGF21 in the
metabolic response to protein restriction. We show
that Fgf21 KO mice are fully resistant to low protein
(LP)-induced changes in food intake, energy expen-
diture (EE), body weight gain, and metabolic gene
expression for 6 months. Gcn2 KO mice recapitulate
this phenotype, but LP-induced effects on food
intake, EE, and body weight subsequently begin to
appear after 14 days on diet. We show that this de-
layed emergence of LP-induced metabolic effects
in Gcn2 KO mice coincides with a delayed but pro-
gressive increase of hepatic Fgf21 expression and
blood FGF21 concentrations over time. These data
indicate that FGF21 is essential for the metabolic
response to protein restriction but that GCN2 is
only transiently required for LP-induced FGF21.INTRODUCTION
Fibroblast growth factor 21 (FGF21) is a circulating hormone
associated with metabolic responses to nutrient restriction, as
initial work demonstrated that FGF21 is increased during fasting,
starvation, and a ketogenic diet (Badman et al., 2007; Inagaki
et al., 2007; Potthoff et al., 2009, 2012). However, our recent
data suggest that reduced protein intake is the primary regulator
of FGF21 during these interventions, and that FGF21-deficient
mice fail to exhibit the increases in food intake, increases in en-
ergy expenditure (EE) and reductions in growth observed in wild-
type mice consuming low-protein diet (Laeger et al., 2014a). The
mechanisms linking reduced protein intake to increased hepatic
Fgf21 expression and secretion are currently unclear, but previ-
ous work implicates the amino acid sensor GCN2 (De Sousa-
Coelho et al., 2012; Laeger et al., 2014a). GCN2 phosphorylatesThis is an open access article under the CC BY-NeIF2a in response to depletion of cellular amino acids (Wek et al.,
1995), leading to the inhibition of general protein synthesis while
increasing the translation of specific transcription factors, such
as ATF4. GCN2-dependent phosphorylation of eIF2a and resul-
tant activation of ATF4 links amino acid availability to meta-
bolism, particularly in the liver (Anthony et al., 2004; Dudek and
Semenkovich, 1995; Guo and Cavener, 2007; Hamanaka et al.,
2005; Xiao et al., 2011; Zhang et al., 2002). The Fgf21 promoter
contains amino acid response elements (AARE), and both deple-
tion of amino acids and activation of this eIF2a/ATF4 pathway in-
creases FGF21 (De Sousa-Coelho et al., 2012; Kim et al., 2013;
Schaap et al., 2013; Wilson et al., 2015). Consistent with these
reports, it was demonstrated that hepatic eIF2a-phosphorylation
is induced in multiple settings of dietary protein restriction, and
that low-protein (LP)-induced increases in FGF21 and eIF2a
phosphorylation are blunted in GCN2-deficient mice (Laeger
et al., 2014a).
Since FGF21 is required for metabolic and behavioral re-
sponses to protein restriction, and GCN2 contributes to the in-
crease of FGF21 in this setting, we hypothesized that GCN2-
deficient mice would fail to respond to reduced dietary protein
intake and thereby recapitulate the phenotype of Fgf21 KO
mice. The results indicate that Gcn2 KO mice do recapitulate
the phenotype of FGF21-KO, but only transiently, such that
GCN2-KO mice begin to respond to LP diet in a fashion similar
to wild-type after approximately 14 days. In contrast, Fgf21 KO
mice never exhibit a metabolic response to protein restriction,
even for 6 months, demonstrating that FGF21 is indeed an
essential signal of protein restriction.RESULTS
FGF21 Is Required for Changes in Food Intake, Energy
Expenditure, and Body Weight Gain
Wild-type (WT) and Fgf21 KO were placed on isocaloric control
and LP diets for 27 weeks (6 months). In wild-type mice, LP
diet significantly impaired body weight gain, with WT-LP mice
losing1 g of body weight (BW) in the first week and then largely
failing to gain weight for the entire 6-month period (Figure 1A).
Over the 6months of dietary exposure theWT-CONmice gained
7.5 ± 1.3 g, while WT-LP mice lost only 0.13 ± 0.8 g, a numberCell Reports 16, 707–716, July 19, 2016 ª 2016 The Author(s). 707
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. FGF21 Is Persistently Required for
Low-Protein-Induced Changes in Body
Weight, Body Composition, Food Intake,
and Energy Expenditure
(A–D) Body weight change in WT (A) and Fgf21 KO
mice (B), body fat change (C), and body lean
change (D) in WT and Fgf21 KOmice on isocaloric
control or LP diet for 27 weeks.
(E and F) Percentage body fat (E) and percentage
body lean (F) at sacrifice on week 27.
(G) Average EE over the 3-day period of EE mea-
surement after 11 weeks on diet.
(H) Average daily food intake over the entire 27-
week period.
(I) Final body length at sacrifice on week 27.
n = 8–10/group, #0.1 > p > 0.05; *p < 0.05; **p <
0.01. Data are represented as mean ± SEM.not statistically different from zero (Figure 1A). The LP-induced
reduction in BW gain was associated with a significant reduction
in fat gain (Figure 1C) and a loss of lean mass (Figure 1D). How-
ever, because the absolute reduction in fat mass gain was much
larger than the loss of lean mass, percentage body fat was actu-
ally reduced, whereas percentage of body lean was increased in
WT-LP mice compared to WT-CON (Figures 1E and 1F). Despite
the reduction in total protein intake, we observe no negative ef-
fect of the LP diet on motor coordination and athleticism in the
rotarod task (Figure S1). Strikingly, these effects of LP diet on
weight gain and adiposity were completely abolished in Fgf21
KO mice, who in fact exhibited increased weight gain when
placed on a LP diet (Figure 1B). FGF21-LP mice also gained
significantly more total body fat (Figure 1C) and did not lose
lean mass (Figure 1D) and therefore exhibited increased body
adiposity (Figure 1E) compared to FGF21-CON. Finally, the ef-
fect of LP to reduce body length in WTmice was also completely
abolished in Fgf21 KO mice (Figure 1I), suggesting that the LP-
induced reduction in weight was associated with a reduction in
linear growth. In summary, the consumption of a LP diet for
27 weeks reduced growth, bodyweight, and total body adiposity
in wild-type but not Fgf21 KO mice.
To understand the mechanism driving these changes in BW
and adiposity with LP diet, we compared food intake and energy708 Cell Reports 16, 707–716, July 19, 2016expenditure (EE) in WT and Fgf21 KO
mice. Our previous work indicated that
WT mice and rats exhibit significant in-
creases in food intake when exposed
to LP diet for 2 weeks (Laeger et al.,
2014a, 2014b; Morrison et al., 2007),
and here this hyperphagic response
extended to the entire 27-week experi-
ment (Figure 1H). The increase in food
intake was accompanied by a persistent
increase in EE, as demonstrated by the
increase in EE in WT-LP mice after
11 weeks on diet (Figures 1G and S2),
and by the fact that the LP-induced hy-
perphagia did not produce weight gain.
Importantly, these long-term effects ofLP diet on food intake and EE were completely absent in Fgf21
KO mice (Figures 1 and S2).
FGF21 Is Required for Changes in Liver Metabolic Gene
Expression
Previouswork focusing onmodels of single amino acid restriction
or deprivation suggest that amino acid restriction alters the
expression of hepatic lipogenic gene expression (Anthony
et al., 2013; Guo and Cavener, 2007), and there is evidence that
FGF21 contributes to these effects (De Sousa-Coelho et al.,
2013). Within the liver, 2 weeks of LP diet consistently reduced
the expression of genes associated with lipogenesis (Scd1,
Fas, and Srebp1), and this effect of LP diet was lost in Fgf21
KOmice (Figure 2A). A tendency for a reduction in Pepck expres-
sion was observed in all groups, although in no group was the ef-
fect statistically significant. Finally, consistent with our previous
work, LP had no significant effect on Ppara mRNA expression
in any group. The effect of LP diet to reduce Srepb1 was lost at
27weeks, while Scd1 and PparamRNA expression was reduced
inWT but not Fgf21KOmice (Figure 2B).Acc1mRNA expression
was induced by LP diet in the Fgf21 KO group at both 2 and
27 weeks. Taken together, these data suggest that the FGF21
is required for LP-induced changes inmetabolic gene expression
within the liver, particularly for genes related to lipid metabolism.
Figure 2. FGF21 Is Required for Effects of
Low-Protein Diet on Hepatic Metabolism
(A and B) WT and Fgf21 KO were placed on
isocaloric control or LP diet for 2 weeks (A) or
27 weeks (B), and mRNA expression was
measured in liver. n = 10/group, #0.1 > p > 0.05;
*p < 0.05; **p < 0.01. Data are represented as
mean ± SEM.FGF21 Is Required for Changes in BAT and iWAT
Thermoregulatory Gene Expression
We next tested whether the robust and persistent increase in en-
ergy expenditure due to LP diet was associated with changes
in BAT or iWAT. Consistent with the acute increase in energy
expenditure induced by LP diet, Ucp1 gene expression (p <
0.01; Figure 3A) and UCP1 protein levels (p < 0.01; Figure 3B)
were significantly increased after 14 days of protein restriction,
although Cidea mRNA expression was not. There was no effect
of LP diet on BATUcp1mRNA or UCP1 protein at 27 weeks (Fig-
ures 3A and 3B), despite evidence for persistent increases in EE.
Importantly, these effects of LP on UCP1 levels at 2 weeks were
lost in FGF21-KO mice.
Considering that FGF21 has been linked to the browning of
iWAT, we next tested whether LP promoted thermogenic gene
expression and browning in iWAT. Unfortunately, iWAT was
not collected at 2 weeks in WT and Fgf21 KO mice. However,
at 27 weeks we observe strong evidence for browning in iWAT.
Levels of Ucp1 and Cidea are robustly increased by LP diet (Fig-
ure 3C), although Pgc1a was not affected. Histological assess-
ment revealed discrete patches of morphological change that
are consistent with browning, including the appearance of multi-
locular adipocytes (Figure 3D). Finally, these effects of LP diet on
iWAT gene expression andmorphology were absent in Fgf21 KO
mice (Figures 3C–3E).
GCN2 Is Required for the Acute Behavioral and
Metabolic Response to Protein Restriction
Our previous work suggested that GCN2 contributes to LP-
induced increases in FGF21 (Laeger et al., 2014a). If FGF21 isCrequired for the metabolic response to
protein restriction, and GCN2 is essential
for the induction of FGF21, thenGcn2 KO
mice should recapitulate the phenotype
of Fgf21 KO mice by not responding
to protein restriction. To assess the acute
response to LP diet, WT and Gcn2
KO mice were placed on LP diet for
14 days. As expected, WT mice on LP
diet displayed a progressive increase in
energy expenditure (Figures 4A and 4C)
during both the light and dark periods.
This effect was evident irrespective of
whether EE was expressed on a per-
animal basis (Figure 4C), normalized to
body weight or lean mass (Figure S3),
or analyzed via analysis of covariance
(ANCOVA) with body weight as the covar-iant (Figure S3). LP diet also induced a trend toward increased
food intake (p = 0.075; Figure 4D). Just as in Fgf21 KO mice,
there was no detectable change in either EE or food intake in
Gcn2 KO mice.
Also as expected, LP diet induced a significant loss of body
weight in WT mice (p < 0.01; Figure 4E), with this weight loss
being largely explained by loss of leanmass (p < 0.01; Figure 4G).
Gcn2 KOmice again failed to respond to LP, as they maintained
their weight during LP diet (Figure 4E) and exhibited no signifi-
cant change in either fat or lean mass (Figures 4F and 4G).
Finally, changes in hepatic lipogenic gene expression were as-
sessed in wild-type andGcn2 KOmice after 14 days (Figure S4),
and here again the Gcn2 KO mice replicate the phenotype of
Fgf21 KO mice by failing to exhibit a decrease Scd, Fas, or
Srebp1 mRNA expression. Collectively, these demonstrate that
Gcn2 KO mice do not exhibit acute metabolic responses to pro-
tein restriction, and as such replicate the phenotype of Fgf21 KO
mice.
GCN2 Is Not Required for Chronic Responses to Dietary
Protein Restriction
To test whether GCN2 was also required for the chronic
response to dietary protein restriction, a separate group of
WT and Gcn2 KO mice were placed on control or LP diets
for 27 weeks (6 months) to replicate the prior study of Fgf21
KO. As before, dietary protein restriction induced significant
and persistent changes in body weight gain, food intake, en-
ergy expenditure, and body composition in wild-type mice
(Figure 5). Consistent with our prior data, this weight reducing
effect of LP diet was not apparent in Gcn2 KO mice at 1 orell Reports 16, 707–716, July 19, 2016 709
Figure 3. FGF21 Is Required for Effects of
Protein Restriction on Metabolic and Ther-
mogenic Gene Expression in BAT and iWAT
(A–E) WT and Fgf21 KO mice were placed on
isocaloric control or LP diet for 2 (A and B) or 27
(A–E) weeks to assess thermogenic gene expres-
sion (A and C), UCP1 protein levels (B), and
metabolic gene expression (E). H&E staining (D) of
inguinal WAT revealed morphological changes
consistent with browning in WT but not Fgf21 KO
mice on LP.
Scale bar, 100 mm. n = 8–10/group, #0.1 > p > 0.05;
*p < 0.05; **p < 0.01. Data are represented as
mean ± SEM.2 weeks (Figure 5B). However, body weight gain began to
diverge between GCN2-Control and GCN2-LP mice at 3 weeks
on diet, and energy expenditure at 11 weeks on diet was
significantly increased in Gcn2 KO mice (Figures 5G and S2).
Daily food intake averaged over the 27-week experiment was
increased in Gcn2 KO mice (Figure 5H), and at the end of
the study LP diet exerted significant effects on body fat and
lean gain and percentage body fat in both wild-type and
Gcn2 KO mice (Figures 5C–5F). Because the response
to LP diet was largely intact in GCN2 mice at the end of
the 27-week experiment, additional tissue endpoints in
these mice were not analyzed. Taken together, these data
suggest that GCN2 is required for LP-induced metabolic re-
sponses through approximately 14 days, but that, in contrast
to FGF21, GCN2 becomes unnecessary after more chronic
dietary exposure.710 Cell Reports 16, 707–716, July 19, 2016FGF21 Levels Progressively
Increase over Time in Association
with a Compensatory Increase in
ATF4 Binding to the FGF21 Gene
Promoter in Gcn2 KO Mice on LP
Diet
To explain this transient contribution
of GCN2, we measured hepatic Fgf21
mRNA expression and circulating
FGF21 protein levels in WT and Gcn2
KO mice over time. As expected, no
Fgf21 mRNA could be detected in the
FGF21 KO mice (Figure 6A), while hepat-
ic Fgf21mRNA expression was markedly
increased by LP diet in wild-type mice at
both 2 and 27 weeks. In Gcn2 KO mice,
this LP-induced increase was greatly
blunted at 2 weeks (19-fold increase in
WT versus 2.7-fold increase in Gcn2
KO). However, at 27 weeks the effect
of LP diet to increase hepatic Fgf21
mRNA expression in Gcn2 KO mice
was fully intact (Figure 6A), such that
Fgf21 mRNA expression in GCN2-LP
mice was increased relative to both
GCN2-CON at 27 weeks (p < 0.01) and
GCN2-LP at 2 weeks (p = 0.029). Consis-tent with Fgf21mRNA expression, plasma levels of FGF21 were
robustly increased in WT mice at 2 weeks (p < 0.01; Figure 6B),
and FGF21 levels remained elevated in WT-LP mice for the
entire 27-week experiment. This LP-induced increase in
FGF21 was significantly blunted in Gcn2 KO mice at 2 weeks,
but blood samples collected in mice following more chronic
dietary exposure (12 and 27 weeks) revealed a progressive
increase in circulating FGF21 in LP-fed Gcn2 KO mice, such
that at 27 weeks serum FGF21 levels in GCN2-LP mice was
increased relative to both GCN2-CON at 27 weeks (p < 0.01)
and GCN2-LP at 2 weeks (p < 0.01). Just as the effects of LP
diet on EE and BW are transiently blunted in Gcn2 KO mice,
LP-induced increases in FGF21 were also transiently blunted
in Gcn2 KO mice.
Finally, we used a chromatin immunoprecipitation assay
(ChIP) in liver tissue to test whether this progressive increase
Figure 4. GCN2 Is Required for Acute LP-Induced Changes in En-
ergy Expenditure, Body Weight, and Body Composition
(A and B) Energy expenditure (EE) in WT (A) and Gcn2 KO (B) mice consuming
isocaloric control or LP diet.
(C) Average EE over days 5 to 7 of diet consumption.
(D) Average daily food intake in WT andGcn2 KOmice over the 14 days of diet
exposure.
(E–G) Change in body weight (E), fat mass (F), and lean mass (G) in WT and
Gcn2 KO mice on control or LP diet for 14 days.
n = 8/group, #0.1 > p > 0.05; *p < 0.05; **p < 0.01. Data are represented as
mean ± SEM.in FGF21 was mirrored by changes in ATF4 binding to the Fgf21
promoter (Figure 6C), as ATF4 is considered to be the transcrip-
tion factor that mediates GCN2-dependent regulation of Fgf21
(De Sousa-Coelho et al., 2012; Schaap et al., 2013). ChIP anal-
ysis demonstrates that LP markedly increases ATF4 binding
to the Fgf21 promoter in WT mice at both 2 (Figure 6D) and
27 (Figure 6E) weeks. In Gcn2 KO mice, this ATF4 binding
was greatly blunted at 2 weeks; however, at 27 weeks ATF4
binding to the Fgf21 promoter was normalized. Thus, binding
of ATF4 to the Fgf21 promoter is highly correlated with the
expression of Fgf21 in response to LP diet. Taken together,
these data indicate that protein restriction induces a robust
and persistent increase in circulating FGF21 in wild-type mice,
and that the delayed metabolic response to LP diet in Gcn2
KO mice is explained by a delayed, GCN2-independent activa-
tion of ATF4 binding activity and a resultant increase in circu-
lating FGF21.DISCUSSION
We previously demonstrated that dietary protein restriction
induces a marked increase in circulating FGF21, and that this in-
crease in FGF21 is required for behavioral and metabolic re-
sponses induced by 2 weeks of protein restriction (Laeger
et al., 2014a). We also demonstrated that the acute, LP-induced
increase in FGF21 (4 days) was greatly blunted inGcn2 KOmice.
The present study extends these data in four important ways.
First, we demonstrate that the robust changes in body weight,
adiposity, energy expenditure, and food intake induced by pro-
tein restriction are accompanied by changes in metabolic gene
expression in liver, BAT, and iWAT. Second, we demonstrate
that these changes persist for at least 6 months of diet exposure.
Third, we show that FGF21 is persistently elevated by dietary
protein restriction and fully required for the metabolic effects
induced by protein restriction at both acute and chronic time
points. These data compellingly demonstrate that FGF21 is
essential for adaptive responses to protein restriction and may
be an endocrine signal that links dietary protein availability to
metabolic function. Finally, our data suggest that GCN2-depen-
dent activation of ATF4 is required for acute effects of LP diet on
both FGF21 induction and metabolic responses, but that over
time additional mechanisms upstream of ATF4 compensate for
the absence of GCN2.
When wild-type C57BL6 mice are placed on a diet containing
5% protein, we observe a series of metabolic changes that are
reminiscent of those induced by general dietary (calorie) restric-
tion. Perhaps the most dramatic effect is the cessation of body
weight gain, as over the 6 months of dietary exposure the wild-
type mice on LP diet lost a miniscule 0.1 g, whereas control
mice gained 7 g. This cessation of body weight gain was also
associated with reductions in both fat and lean mass gain, and
a reduction in body length. While LP diet produced a significant
loss of lean mass, this loss was counterbalanced by a much
larger reduction in fat gain. As a result, WT-LP mice were leaner
(reduced percentage fat) than their controls. It is possible that
consuming a diet containing only 5% protein might exert nega-
tive effects on muscle growth and performance, and we there-
fore assessed athletic performance and coordination using the
rotarod. Interestingly, WT-LP exhibited either no change or an
improvement in rotarod performance in the two studies we con-
ducted. Thus, despite the rather marked reduction in protein
intake, our data provide no evidence that this level of protein re-
striction exerts marked negative effects on health or muscular
function, at least through 6 months of diet exposure.
Dietary protein restriction is known to increase both food
intake and energy expenditure (Gosby et al., 2014; Hasek
et al., 2010; Laeger et al., 2014a, 2014b; Morrison et al., 2007;
Rothwell and Stock, 1987; Rothwell et al., 1983; Simpson and
Raubenheimer, 1997, 2005; White et al., 2000). We observe
similar effects in the current data and demonstrate that these
changes are persistent over the entire 6-month experiment.
Although EE was only measured at week 1 and week 11, it was
increased at both time points and food intake was increased
throughout the experiment, including the last few weeks of die-
tary treatment. The maintenance of hyperphagia without weight
gain strongly implies that EE was significantly increased for theCell Reports 16, 707–716, July 19, 2016 711
Figure 5. GCN2 Is Not Required for Long-
Term Low-Protein-Induced Changes in
Body Weight, Body Composition, Food
Intake, and Energy Expenditure
(A–D) Body weight change in WT (A) and Gcn2 KO
mice (B), body fat change (C), and body lean
change (D) in WT and Gcn2 KO mice on isocaloric
control or LP diet for 27 weeks.
(E and F) Percentage body fat (E) and percentage
body lean (F) at sacrifice on week 27.
(G) Average EE over the 3-day period of EE mea-
surement after 11 weeks on diet.
(H) Average daily food intake over the entire 27-
week period.
n = 8/group, #0.1 > p > 0.05; *p < 0.05; **p < 0.01.
Data are represented as mean ± SEM.entire 6-month period. These data suggest that the reduction in
long-term body weight gain is driven largely by this robust and
persistent increase in whole-body energy expenditure, with the
concomitant hyperphagia being an adaptive response to avoid
weight loss and increase protein intake.
Remarkably, the robust and persistent effects of dietary pro-
tein restriction on feeding behavior, energy expenditure, body
weight gain, and metabolic gene expression were completely
absent in FGF21 KO mice. These data clearly demonstrate that
FGF21 is robustly induced by the specific reduction of protein
intake, that FGF21 levels remained elevated for the duration of
protein restriction (through 6months), and that FGF21 is required
for adaptive responses to protein restriction. The fact that Fgf21
KO mice grew normally, despite consuming the same LP diet as
controls, also leads to the interesting conclusion that the LP-
induced reduction in growth and BW gain were not directly
due an insufficient supply of amino acids to support growth,
but instead due to the FGF21-dependent metabolic response
induced by protein restriction.
Previouswork from our lab and others suggests that the amino
acid sensor GCN2 may be a key molecular link driving the in-
creases in FGF21 observed during amino acid restriction (De
Sousa-Coelho et al., 2012; Laeger et al., 2014a; Wilson et al.,
2015). If GCN2 is indeed required for LP-induced increases in712 Cell Reports 16, 707–716, July 19, 2016FGF21, then Gcn2 KO mice, like Fgf21
KO mice, should be largely unresponsive
to dietary protein restriction. Our data
support this conclusion since food
intake, EE, and body weight gain were
not altered by LP diet in Gcn2 KO mice
through 14 days. However, subsequent
long-term studies yielded a much
different result. Body weight began to
diverge between GCN2-CON and
GCN2-LP mice at 3 weeks (in WT mice
the divergence appears immediately at
1 week). Similarly, although there was
no effect of LP diet to increase EE or
food intake inGcn2 KOmice over the first
7 days of diet exposure, a clear increase
EE and food intake was observed whenGcn2 KO mice were tested at 11 weeks. Therefore, these data
suggest that the contribution of GCN2 to themetabolic response
to protein restriction is only transient.
Our data indicate that this transitory contribution of GCN2 is
largely explained by changes in circulating FGF21. As previously
shown and discussed above, dietary protein restriction induces
an acute, robust, and persistent increase in both hepatic Fgf21
mRNA and circulating FGF21 protein. This acute induction of
FGF21 by LP diet is markedly blunted in Gcn2 KO mice, and it
seems likely that the lack of response to LP diet in Gcn2 KO
mice is explained by this blunted increase in FGF21. However,
LP diet still produces a small increase in FGF21 in GCN2-KO
mice at 4 (Laeger et al., 2014a) and 14 days, suggesting that
GCN2 is not the sole driver of FGF21 during protein restriction.
Most importantly, this GCN2-independent effect is mobilized
over time, such that FGF21 levels progressively rise in GCN2-
LP mice. Currently, the identity of this GCN2-independent path-
way(s) is unclear, but our data suggest that the compensation
occurs upstream of the transcription factor ATF4. ATF4 has
been previously linked to amino-acid-dependent FGF21 regula-
tion, as it was shown that ATF4 binds to the Fgf21 promoter and
is required for induction of FGF21 in response to amino acid
restriction (De Sousa-Coelho et al., 2012; Schaap et al., 2013).
Our data demonstrate that the binding of ATF4 to the FGF21
Figure 6. The Delayed Response to Protein
Restriction in Gcn2 KO Mice Is Explained
by a Delayed, ATF4-Dependent Increase in
FGF21
(A) Liver Fgf21mRNA expression inWT, Fgf21 KO,
and Gcn2 KO after 2 and 27 weeks on isocaloric
control or LP diets.
(B) Circulating FGF21 protein levels assessed by
ELISA in WT and Gcn2 KO mice consuming con-
trol or LP diet for 2, 12, and 27 weeks.
(C) Schematic representation of the mouse Fgf21
promoter containing the distal (ATF4RE1) and
proximal (ATF4RE2) genomic response elements
recognized by ATF4. A negative control region
without ATF4 binding sites is also shown. Arrows
indicate the respective regions within the gene
promoter targeted for amplification by qPCR.
(D and E) ChIP assays were performed using liver
tissue from mice after 2 (D) or 27 (E) weeks on LP
diet.
n = 8–10/group, except n = 3/group for (D) and (E).
*p < 0.05; **p < 0.01. Data are represented as
mean ± SEM.promoter in the liver is robustly and persistently increased by di-
etary protein restriction. In addition, a GCN2-dependent activa-
tion of ATF4 signaling appears to be a keymechanism underlying
the acute induction of FGF21 following protein restriction, as
ATF4 binding is blunted in the Gcn2 KO mice after 2 weeks on
LP diet. However, just as GCN2 is not required for the LP-
induced increases in FGF21 over longer periods, GCN2 is also
not required for the LP-induced binding of ATF4 to the Fgf21 pro-
moter. Thus, some additional pathway, upstream of ATF4, com-
pensates for the absence of GCN2 following long-term protein
restriction. Whether this pathway contributes to Fgf21 expres-
sion in wild-type mice, or is instead only recruited in the absence
of GCN2, remains unclear.
Finally, these data also conceptually suggest that FGF21
levels must increase above a threshold before they exert marked
effects on body weight or EE. In other words, our data in Gcn2
KO mice suggest that FGF21 concentrations below approxi-
mately 2 ng/ml are insufficient to drive marked metabolic effects
in mice, but that changes in EE and BW are readily observed
when concentrations approach 4 ng/ml. Additional work is
required to precisely define this threshold concentration and
to extrapolate it to other contexts, but these data suggest
that fold increases in FGF21 that appear large (from 0.3 to
1.48 ng/ml or 5-fold) may still be insufficient to drive metabolic
responses.
In addition to inducing changes in whole-body energy expen-
diture, FGF21 also acts on multiple tissues to coordinate
substrate metabolism and cellular function (Kharitonenkov and
Adams, 2013; Owen et al., 2015).We therefore analyzed a variety
of genes associated with carbohydrate and lipid metabolism in
liver, iWAT, and BAT. Consistent with the reduction in fat gain
and adiposity in WT-LP mice, genes associated with hepaticClipogenesis were significantly reduced in
WT-LP mice after 14 days on diet, and
these effects were absent in both Gcn2KO and Fgf21 KO mice. These data are consistent with prior
work in mice using diets devoid of a single amino acid (De
Sousa-Coelho et al., 2013; Guo and Cavener, 2007), and previ-
ous work in rats demonstrating that single amino acid restriction
potently alters lipid metabolism in liver and adipose tissue (Ha-
sek et al., 2013). FGF21 also promotes thermogenic activity in
BAT and WAT (Adams et al., 2012; Douris et al., 2015; Fisher
et al., 2012; Lee et al., 2014), and it might therefore be expected
that the chronic induction of FGF21 induces thermogenic activa-
tion of these tissues (De Sousa-Coelho et al., 2013). Long-term
protein restriction significantly increased both UCP1 and Cidea
mRNA within iWAT in association with morphological changes
consistent with browning, and these effects were absent in
Fgf21 KO mice. Whether these effects on WAT and BAT are
required for the persistent increase in EE and reduction in body
weight gain observed with long-term dietary protein restriction
remains unclear, as recent reports suggest that the effects of
FGF21 on EEmay not require UCP1 or WAT browning (Bernardo
et al., 2015; Samms et al., 2015; Ve´niant et al., 2015), although
UCP1 appears contribute to the metabolic effects induced by
dietary restriction of just the amino acid methionine (Wanders
et al., 2015).
There is ample evidence supporting the existence of regula-
tory mechanisms that sense nutrient depletion and coordinate
adaptive metabolic and behavioral responses (Morrison and
Berthoud, 2007), and it seems likely that protein intake is also
regulated via a mechanism that is independent of energy intake
(Morrison and Laeger, 2015; Morrison et al., 2012). Long-term
dietary protein restriction induces a series of behavioral and
metabolic effects that, perhaps contrary to expectations, result
in ‘‘beneficial’’ changes in energy expenditure, body weight,
and adiposity that are consistent with the well-described effectell Reports 16, 707–716, July 19, 2016 713
of dietary restriction on health and longevity (Solon-Biet et al.,
2015). Our data strongly suggest that FGF21 is an endocrine hor-
mone that plays a key biological role in the mediating these
adaptive responses to protein restriction.
EXPERIMENTAL PROCEDURES
Animals and Diets
All procedures involving animals were approved by the PBRC Institutional An-
imal Care and Use Committee. Male C57BL6 mice (The Jackson Laboratory)
were used in all studies. GCN2-deficient mice on the B6 backgroundwere pur-
chased from The Jackson Laboratory (Stock #:008240). FGF21-deficient mice
on the B6 background were kindly provided by Dr. Steven Kliewer (UT South-
western) as described previously (Potthoff et al., 2009). Control and LP diets
were formulated and produced by Research Diets, and were designed to be
isocaloric by equally varying protein and carbohydrate while keeping fat con-
stant. Control diet contained 20% casein (by weight) as the protein source,
while the LP diet contained 5% casein. On an energy basis the diets contained
protein at 18% (control) and 4% (LP). A detailed dietary composition is pro-
vided in Table S1. Animals were single housed in 12:12-hr light:dark cycle
with ad libitum access to food or water unless otherwise noted.
For general effects of dietary protein restriction, single housed mice were
transferred from chow to the control diet for approximately 5 days, at which
point a random subgroup of animals were transferred to the respective LP
diet. Animals consumed control or LP diet ad libitum for the duration of the
study until they were sacrificed and liver, inguinal white adipose tissue
(iWAT), and brown adipose tissue (BAT) were collected and snap frozen for
further analysis. Mice were sacrificed during the mid-light cycle in the fed state
(unless otherwise noted) using acute exposure to CO2 followed by rapid
decapitation. Trunk blood was also collected at sacrifice, allowed to clot over-
night at 4C, centrifuged at 3,000 3 g and serum collected.
Acute Response to LP Diet in GCN2 and FGF21-Deficient Mice
Gcn2 KO and WTmice (eight mice/diet/genotype) were initially adapted to the
control diet while in metabolic chambers (OxyMax/CLAMS, Columbus Instru-
ments), were transitioned to the LP diet while in the OxyMax, and remained in
the OxyMax for the first 7 days of dietary exposure. Afterward, mice were re-
turned to standard caging for the final 7 days, and after 14 days on diet were
sacrificed and the tissue was collected as described above. Body weight and
food intake were collected four times through the 14-day experiment. Body
composition was measured via TD-NMR (Bruker Minispec) on the start of
experimental diets (day 0), the final day of OxyMax metabolic analysis
(day 7), and on the day of sacrifice (day 14). FGF21-deficient (Fgf21 KO)
mice were treated as above, with LP-dependent effects on metabolic gene
expression within liver and BAT described in this manuscript, while data
related to changes in body weight, energy expenditure, and food intake
have been previously published for these mice (Laeger et al., 2014a).
Chronic Response to LP Diet in GCN2 and FGF21-Deficient Mice
15-week-old Gcn2 KO, Fgf21 KO, and WT mice were adapted to control diet
and then randomly placed on either control or LP diet (eight mice/diet/geno-
type) for 27 weeks. Body weight and food intake were collected every
7 days during the experiment. Body composition was measured via TD-
NMR (Bruker Minispec) every 14 days until the end of the experiment. After
11 weeks on diet, mice were placed into metabolic chambers (OxyMax) for
3 days to assess energy expenditure, respiratory exchange ratio, and activity
(beam breaks), after whichmice were returned to standard caging until the end
of the experiment. After 12 weeks on the diet, blood was collected via the
saphenous vein from Gcn2 KO and corresponding WT mice to analyze
FGF21. After 20 weeks on diet, motor function and coordination were tested
via Rotarod (Med-Associates). In this test, mice are placed on a slowly accel-
erating rod, progressing from 4 to 40 rpm during a period of 300 s, and the la-
tency to fall was recorded for each animal. Mice were given three trials, with an
inter-trial interval of 30 min. Each mouse was acclimated to the movement of
the rod and then to its acceleration for 1 min during an initial training session
the day before the first test session. Finally, Gcn2 KO and Fgf21 KO with cor-714 Cell Reports 16, 707–716, July 19, 2016responding WT mice were sacrificed after 27 weeks and tissue collected as
described above.
Immunoassay Determination of FGF21
Concentrations of FGF21 in serum were determined in mice with an ELISA ac-
cording to the procedure recommended by the manufacturer (no.
RD291108200R, Mouse and Rat FGF-21 ELISA, BioVendor). The minimal
detectable concentration of FGF21 with this assay was 18.4 pg/ml. The intra-
and inter-assay coefficients of variation for the mouse and rat FGF21 assay
were both <9.0%, respectively. For determination of serum FGF21, 50 ml of
serum was diluted in 200 ml of dilution buffer before analysis.
Real-Time PCR
RNA extraction and real-time PCR were conducted as described previously
(Morrison et al., 2007). Total RNA was extracted from liver, iWAT, and BAT
using TRIzol reagent following the manufacturer’s protocol (15596018, Invitro-
gen). RNA quality and quantity was determined by spectrophotometry using a
NanoDrop (Thermo Scientific). cDNA synthesis was performed with M-MLV
reverse transcriptase (M1701, Promega), and mRNA was quantified on the
ABI 7900 platform using the SYBR green methodology in optical 384-well
plates (Applied Biosystems). Primer pairs were designed using NCBI Primer-
BLAST with at least one primer spanning an exon-exon boundary. Target
gene expression was normalized with cylcophilin B as the endogenous
control.
H&E Staining
Paraffin sections of inguinal WAT were mounted on slides and dewaxed
through immersion in xylene substitute, 100% ethanol, and 95% ethanol, prior
to a water immersion step. The slides were then stained 3 min in hematoxylin,
washed, immersed in Define solution 1 min, washed, immersed in bluing solu-
tion 1 min, washed, dehydrated with 95% ethanol 1 min, stained with eosin,
and then dehydrated through 100% ethanol and xylene substitute prior to cov-
erslipping. All staining was done on a Leica ST5020 autostainer.
Western Blot
BAT was added frozen and immediately minced in cold whole-cell lysate
buffer with protease and phosphatase inhibitors, followed by sonication
and centrifugation. 5–10 mg of supernatant from centrifugation was used for
subsequent western blotting on a standard 10% SDS-PAGE gel in a Bio-
Rad electrophoresis system in Laemmli loading sample buffer. Blots were
blocked with Odyssey blocking buffer (LI-COR Biosciences) in nitrocellulose
membrane and then incubated overnight at 4C with primary antibodies.
Ucp-1 (ab10983) antibody was also obtained from Abcam, at a dilution of
1:4,000, and alpha-tubulin (1:4,000, Abcam ab7291) was used as an internal
control. The next morning, they were washed and then probed with LI-COR
Biosciences IR secondary antibodies at 1:5,000 for 1 hr at room temperature
(Odyssey Secondary antibody: Donkey IRDye 800CW anti-rabbit immuno-
globulin G (IgG) [H+L] [926-32213] and Odyssey Secondary antibody: Donkey
IRDye 680LT anti-mouse IgG [H+L] [926-68022]), washed again, and then
imaged on LI-COR Odyssey.
Chromatin Immunoprecipitation
Mouse liver tissue (30–50 mg) was thawed on ice and chopped into 1- to
3-mm3 pieces using a clean razor blade. Tissue was placed in a 1.5-ml tube,
and 1 ml of crosslinking solution (1% formaldehyde-HEPES-NaOH [pH 7.8])
was added. Tubes were rotated for 10 min at room temp. Crosslinking was
stopped by adding glycine to a final concentration of 125 mM, and tubes
were rotated for an additional 5 min at room temp. Tissue pellets were
collected by centrifugation at 500 3 g for 5 min at 4C and washed with
1 ml ice-cold PBS, followed by centrifugation at 500 3 g for an additional
5 min at 4C. Supernatants were discarded, and tissue was lysed in 0.9 ml
SDS lysis buffer containing 1 3 protease inhibitors. Lysates were incubated
at 4C, with end-over-end mixing, for 30 min. Lysates were separated into
33 300 ml aliquots in polystyrene sonication tubes and sonicated at 4C using
a Bioruptor Pico (Diagenode). The following sonication conditions generated
fragments of DNA between 100 and 500 bp in length: 30 s on, 30 s off, ten cy-
cles. Tubes were incubated on ice for 15 min and sonication was repeated for
five more cycles. Aliquots were recombined into one tube and centrifuged
at 12,000 3 g for 10 min at 4C. Supernatants were transferred to a clean
microcentrifuge tube. Protein concentration in lysates was determined by
BCA assay (Thermo Scientific). 750 mg sheared, cross-linked DNA was diluted
10-fold in dilution buffer containing 13 protease inhibitors. 11 ml of ATF4 anti-
body, or control rabbit IgG, was added and incubated overnight at 4C with
end-over-end mixing. Immunoprecipitation of DNA-protein-antibody com-
plexes was performed by incubation with 40 ml Protein G Dynabeads (Invitro-
gen) for 1 hr at 4C with end-over-end mixing. The magnetic beads binding to
the antibody-antigen-chromatin complexes were washed sequentially for
5 min each at 4C with 0.5 ml buffers 1–4. 100 ml chelating resin was added,
vortexed for 10 s, and heated to 100C for 10 min. Following centrifugation
at 17,0003 g for 1min at 4C, the supernatants were transferred to new tubes.
A total of 120 ml nuclease-free water was added, vortexed, and recentrifuged.
Supernatants were pooled. Inputs were processed as follows: 90 ml (10%) son-
icated DNAwas incubated overnight at 65Cwith NaCl to a final concentration
of 200 mM. Input DNA was then treated with RNase A for 30 min at 37C and
proteinase K for 1 hr at 45C, followed by purification using a QIAGEN Cleanup
kit (QIAGEN). Input DNA was run on a 2% agarose gel to test for sonication
efficiency. 5 ml DNA was used as a template for downstream SYBR-Green-
based PCRs. All data showing specific binding events are represented as
percentage of input. Buffers and chelating resin were from the ExactaChIP
Chromatin Immunoprecipitation Kit (R&D Systems). ATF4 antibody was from
Cell Signaling Technology (catalog no. 11815). Primer sequences used for
amplifying the distal (ATF4RE1) and proximal (ATF4RE2) ATF4 binding sites,
as well as a negative control region, within the mouse Fgf21 promoter were
from Shimizu et al. (2015).
Statistical Analysis
Data were analyzed using the SAS software package (SAS v.9, SAS Institute)
using one-way or two-way ANOVA, or repeated-measures ANOVA, using the
general linear model procedure. When experiment-wide tests were significant,
post hoc comparisons were made using the LSMEANS statement with the
PDIFF option, and represent least significant differences tests for pre-planned
comparisons. Analysis of energy expenditure with body weight as the covari-
ate was assessed via analysis of covariance (ANCOVA) using the general linear
model procedure of SAS, with results validated against the MMPC.org
ANCOVA data analysis tool. All data are expressed as mean ± SEM, with a
probability value of 0.05 considered statistically significant.
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